Skip to main content
Figure 4 | BMC Immunology

Figure 4

From: Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation

Figure 4

Epitope determination of LaDR5 or TRAIL. A: design and purification of wild type DR5 (DR5WT) and its mutants (DR5M1, DR5M2 and DR5M3) in prokaryotic system, indicating the mutable sites above. SDS-PAGE analysis showed satisfactory purification of DR5s. 1: Protein marker; 2: DR5WT; 3: DR5M1; 4: DR5M2; 5: DR5M3. B: Epitope identification of LaDR5 by ELISA. 5 μg/mL DR5WT or its mutants was coated overnight and incubated with diluted TRAIL or LaDR5. It was showed that mutation of residues 59/62/67/68 or 96/98/101/104 in DR5 attenuated the DR5 binding capacity of LaDR5 or TRAIL, suggesting that they were key residues of DR5 identified by both TRAIL and LaDR5; besides, residues 59/62/67/68 seemed more important, which were consistent with theoretical results predicted by computer-aided analysis. The experimental error is the SD from three independent experiments.

Back to article page